BiotechTube

OCU400

Pre-clinicalActive
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Retinitis Pigmentosa

Conditions

Retinitis Pigmentosa

Trial Timeline

— → —

NCT ID
NCT06574997

About OCU400

OCU400 is a pre-clinical stage product being developed by Ocugen for Retinitis Pigmentosa. The current trial status is active. This product is registered under clinical trial identifier NCT06574997. Target conditions include Retinitis Pigmentosa.

What happened to similar drugs?

0 of 3 similar drugs in Retinitis Pigmentosa were approved

Approved (0) Terminated (0) Active (3)
🔄Valganciclovir + GanciclovirRochePhase 3
🔄GanciclovirRochePhase 3
🔄ValganciclovirRochePhase 3

Hype Score Breakdown

Clinical
3
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06574997Pre-clinicalActive

Competing Products

20 competing products in Retinitis Pigmentosa

See all competitors
ProductCompanyStageHype Score
DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3Sumitomo PharmaPhase 1/2
39
AGN-151597AbbViePhase 1/2
32
CPK850NovartisPhase 1/2
36
Valganciclovir + GanciclovirRochePhase 3
40
ValganciclovirRochePre-clinical
26
Foscarnet sodium + GanciclovirRochePhase 1
29
GanciclovirRochePhase 1
29
GanciclovirRochePre-clinical
26
GanciclovirRochePhase 2
35
GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
Zidovudine + Sargramostim + GanciclovirRochePre-clinical
26
Zidovudine + GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
Interferon beta-1b + GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
GanciclovirRochePre-clinical
26
GanciclovirRochePhase 3
40
ValganciclovirRochePhase 3
36
Cidofovir + ProbenecidGilead SciencesPre-clinical
26